Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V P Zherdev

Showing results (61-70 of 97) with videos related to

Pageof 10
Sort By:
Bulletin of Experimental Biology and Medicine|May 7, 2008
Experimental study of the pharmacokinetics of a tryptophan-containing dipeptide GB-115S S Boyko, G B Kolyvanov, V P Zherdev, et al.
Eksperimental'Naia I Klinicheskaia Farmakologiia|June 7, 2005
[Biotransformation of mexidol in inbred BALB/C and C57BL/6 mice]S B Seredenin, O Iu Kravtsova, A K Sarieva, et al.
Eksperimental'Naia I Klinicheskaia Farmakologiia|April 8, 2016
[EVALUATION OF THE PHARMACOKINETIC INTERACTION OF AFOBAZOLE WITH CYP2C9 ENZYME DRUG SUBSTRATE OF CYTOCHROME P450]O G Gribakina, G B Kolyvanov, A A Litvin, et al.
Bulletin of Experimental Biology and Medicine|February 2, 2008
Tissue availability of afobazole and its major metabolites in ratsA O Viglinskaya, G B Kolyvanov, A A Litvin, et al.
Eksperimental'Naia I Klinicheskaia Farmakologiia|April 15, 2004
[Interspecies differences of noopept pharmacokinetics]S S Boĭko, S A Korotkov, V P Zherdev, et al.
Eksperimental'Naia I Klinicheskaia Farmakologiia|August 1, 2009
[HPLC-MS determination of 2-ethyl-6-methyl-3-oxypyridine]P A Baranov, S A Appolonova, M A Dikunets, et al.
Bulletin of Experimental Biology and Medicine|January 20, 2011
Comparative analysis of tissue availability for afobazole and compound M-11A O Viglinskaya, D V Bastrygin, G B Kolyvanov, et al.
Eksperimental'Naia I Klinicheskaia Farmakologiia|May 16, 2009
[Therapeutic effect and pharmacokinetics of transdermal phenazepam preparation in patients with different anxiety disorders]O A Dorofeeva, S A Siuniakov, V P Zherdev, et al.
Eksperimental'Naia I Klinicheskaia Farmakologiia|February 22, 2014
[In vivo evaluation of the metabolic ratio of CYP2C9 and CYP1A2 drug markers after administration of afobazole in comparison to standard inducers and inhibitors of cytochromes]Ia G Novitskaia, O G Gribakina, G B Kolyvanov, et al.
Bulletin of Experimental Biology and Medicine|January 10, 2022
Preclinical Pharmacokinetics of GZK-111, a Dipeptide with Neuroprotective ActivityA A Litvin, G B Kolyvanov, P O Bochkov, et al.
Pageof 10

Showing results (61-70 of 97) with videos related to

Sort By:
Pageof 10
Bulletin of Experimental Biology and Medicine|May 7, 2008
Experimental study of the pharmacokinetics of a tryptophan-containing dipeptide GB-115S S Boyko, G B Kolyvanov, V P Zherdev, et al.
Eksperimental'Naia I Klinicheskaia Farmakologiia|June 7, 2005
[Biotransformation of mexidol in inbred BALB/C and C57BL/6 mice]S B Seredenin, O Iu Kravtsova, A K Sarieva, et al.
Eksperimental'Naia I Klinicheskaia Farmakologiia|April 8, 2016
[EVALUATION OF THE PHARMACOKINETIC INTERACTION OF AFOBAZOLE WITH CYP2C9 ENZYME DRUG SUBSTRATE OF CYTOCHROME P450]O G Gribakina, G B Kolyvanov, A A Litvin, et al.
Bulletin of Experimental Biology and Medicine|February 2, 2008
Tissue availability of afobazole and its major metabolites in ratsA O Viglinskaya, G B Kolyvanov, A A Litvin, et al.
Eksperimental'Naia I Klinicheskaia Farmakologiia|April 15, 2004
[Interspecies differences of noopept pharmacokinetics]S S Boĭko, S A Korotkov, V P Zherdev, et al.
Eksperimental'Naia I Klinicheskaia Farmakologiia|August 1, 2009
[HPLC-MS determination of 2-ethyl-6-methyl-3-oxypyridine]P A Baranov, S A Appolonova, M A Dikunets, et al.
Bulletin of Experimental Biology and Medicine|January 20, 2011
Comparative analysis of tissue availability for afobazole and compound M-11A O Viglinskaya, D V Bastrygin, G B Kolyvanov, et al.
Eksperimental'Naia I Klinicheskaia Farmakologiia|May 16, 2009
[Therapeutic effect and pharmacokinetics of transdermal phenazepam preparation in patients with different anxiety disorders]O A Dorofeeva, S A Siuniakov, V P Zherdev, et al.
Eksperimental'Naia I Klinicheskaia Farmakologiia|February 22, 2014
[In vivo evaluation of the metabolic ratio of CYP2C9 and CYP1A2 drug markers after administration of afobazole in comparison to standard inducers and inhibitors of cytochromes]Ia G Novitskaia, O G Gribakina, G B Kolyvanov, et al.
Bulletin of Experimental Biology and Medicine|January 10, 2022
Preclinical Pharmacokinetics of GZK-111, a Dipeptide with Neuroprotective ActivityA A Litvin, G B Kolyvanov, P O Bochkov, et al.
Pageof 10